SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern
The continuous transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has required that diagnostic capabilities be constantly monitored and updated as new variants emerge and prior variants disappear. Although whole genome sequencing provides full characterisation...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497716/ https://www.ncbi.nlm.nih.gov/pubmed/36140458 http://dx.doi.org/10.3390/diagnostics12092056 |
_version_ | 1784794574926905344 |
---|---|
author | Lowry, Kym Wang, Claire Bordin, Amanda Buckley, Cameron Badman, Steven Harris, Patrick Mackay, Ian Whiley, David |
author_facet | Lowry, Kym Wang, Claire Bordin, Amanda Buckley, Cameron Badman, Steven Harris, Patrick Mackay, Ian Whiley, David |
author_sort | Lowry, Kym |
collection | PubMed |
description | The continuous transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has required that diagnostic capabilities be constantly monitored and updated as new variants emerge and prior variants disappear. Although whole genome sequencing provides full characterisation of SARS-CoV-2 directly from patient samples, this has limited throughput and requires sufficient resources. To enhance screening for circulating variants, we designed a rapid in-house RT-PCR assay to target a spike mutation (D950N) in Delta variants, which is not detected in the remaining variants of concern (VOCs). Assay sensitivity for detecting Delta variants was 93% and specificity was 100% using a sequenced sample bank of several lineages. As the D950N mutation is prevalent in >95% of the global Delta variant sequences deposited in GISAID, this assay has the potential to provide rapid results to determine if the samples are presumptively Delta variants and can support clinicians in timely clinical decision-making for effective treatments and surveillance. |
format | Online Article Text |
id | pubmed-9497716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94977162022-09-23 SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern Lowry, Kym Wang, Claire Bordin, Amanda Buckley, Cameron Badman, Steven Harris, Patrick Mackay, Ian Whiley, David Diagnostics (Basel) Communication The continuous transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has required that diagnostic capabilities be constantly monitored and updated as new variants emerge and prior variants disappear. Although whole genome sequencing provides full characterisation of SARS-CoV-2 directly from patient samples, this has limited throughput and requires sufficient resources. To enhance screening for circulating variants, we designed a rapid in-house RT-PCR assay to target a spike mutation (D950N) in Delta variants, which is not detected in the remaining variants of concern (VOCs). Assay sensitivity for detecting Delta variants was 93% and specificity was 100% using a sequenced sample bank of several lineages. As the D950N mutation is prevalent in >95% of the global Delta variant sequences deposited in GISAID, this assay has the potential to provide rapid results to determine if the samples are presumptively Delta variants and can support clinicians in timely clinical decision-making for effective treatments and surveillance. MDPI 2022-08-24 /pmc/articles/PMC9497716/ /pubmed/36140458 http://dx.doi.org/10.3390/diagnostics12092056 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Lowry, Kym Wang, Claire Bordin, Amanda Buckley, Cameron Badman, Steven Harris, Patrick Mackay, Ian Whiley, David SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title | SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title_full | SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title_fullStr | SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title_full_unstemmed | SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title_short | SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern |
title_sort | sars-cov-2 rt-pcr to screen for b.1.617.2 (delta) variant of concern |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497716/ https://www.ncbi.nlm.nih.gov/pubmed/36140458 http://dx.doi.org/10.3390/diagnostics12092056 |
work_keys_str_mv | AT lowrykym sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT wangclaire sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT bordinamanda sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT buckleycameron sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT badmansteven sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT harrispatrick sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT mackayian sarscov2rtpcrtoscreenforb16172deltavariantofconcern AT whileydavid sarscov2rtpcrtoscreenforb16172deltavariantofconcern |